JP2020537542A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537542A5 JP2020537542A5 JP2020540681A JP2020540681A JP2020537542A5 JP 2020537542 A5 JP2020537542 A5 JP 2020537542A5 JP 2020540681 A JP2020540681 A JP 2020540681A JP 2020540681 A JP2020540681 A JP 2020540681A JP 2020537542 A5 JP2020537542 A5 JP 2020537542A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- itr
- sequence
- raav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims 31
- 108020004707 nucleic acids Proteins 0.000 claims 29
- 102000039446 nucleic acids Human genes 0.000 claims 29
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 claims 26
- 239000013608 rAAV vector Substances 0.000 claims 20
- 241000702421 Dependoparvovirus Species 0.000 claims 14
- 230000002401 inhibitory effect Effects 0.000 claims 14
- 239000013598 vector Substances 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 11
- 238000002347 injection Methods 0.000 claims 9
- 239000007924 injection Substances 0.000 claims 9
- 239000002773 nucleotide Substances 0.000 claims 7
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- 108090000565 Capsid Proteins Proteins 0.000 claims 6
- 102100023321 Ceruloplasmin Human genes 0.000 claims 6
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 claims 6
- 108700019146 Transgenes Proteins 0.000 claims 5
- 108091070501 miRNA Proteins 0.000 claims 4
- 239000002679 microRNA Substances 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108091026890 Coding region Proteins 0.000 claims 3
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 claims 3
- 241001492404 Woodchuck hepatitis virus Species 0.000 claims 3
- 102000003802 alpha-Synuclein Human genes 0.000 claims 3
- 108090000185 alpha-Synuclein Proteins 0.000 claims 3
- 108010006025 bovine growth hormone Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 3
- 239000013612 plasmid Substances 0.000 claims 3
- 230000001124 posttranscriptional effect Effects 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- 241000701447 unidentified baculovirus Species 0.000 claims 3
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 238000007913 intrathecal administration Methods 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 241000238631 Hexapoda Species 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022007759A JP2022060228A (ja) | 2017-10-03 | 2022-01-21 | ライソゾーム病の遺伝子治療 |
| JP2023192753A JP2024014935A (ja) | 2017-10-03 | 2023-11-13 | ライソゾーム病の遺伝子治療 |
| JP2024001041A JP2024037189A (ja) | 2017-10-03 | 2024-01-09 | ライソゾーム病の遺伝子治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762567303P | 2017-10-03 | 2017-10-03 | |
| US201762567305P | 2017-10-03 | 2017-10-03 | |
| US62/567,305 | 2017-10-03 | ||
| US62/567,303 | 2017-10-03 | ||
| PCT/US2018/054223 WO2019070891A1 (en) | 2017-10-03 | 2018-10-03 | GENE THERAPIES FOR LYSOSOMAL DISORDERS |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022007759A Division JP2022060228A (ja) | 2017-10-03 | 2022-01-21 | ライソゾーム病の遺伝子治療 |
| JP2023192753A Division JP2024014935A (ja) | 2017-10-03 | 2023-11-13 | ライソゾーム病の遺伝子治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020537542A JP2020537542A (ja) | 2020-12-24 |
| JP2020537542A5 true JP2020537542A5 (enExample) | 2021-11-11 |
Family
ID=65995011
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540681A Pending JP2020537542A (ja) | 2017-10-03 | 2018-10-03 | ライソゾーム病の遺伝子治療 |
| JP2022007759A Pending JP2022060228A (ja) | 2017-10-03 | 2022-01-21 | ライソゾーム病の遺伝子治療 |
| JP2023192753A Pending JP2024014935A (ja) | 2017-10-03 | 2023-11-13 | ライソゾーム病の遺伝子治療 |
| JP2024001041A Pending JP2024037189A (ja) | 2017-10-03 | 2024-01-09 | ライソゾーム病の遺伝子治療 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022007759A Pending JP2022060228A (ja) | 2017-10-03 | 2022-01-21 | ライソゾーム病の遺伝子治療 |
| JP2023192753A Pending JP2024014935A (ja) | 2017-10-03 | 2023-11-13 | ライソゾーム病の遺伝子治療 |
| JP2024001041A Pending JP2024037189A (ja) | 2017-10-03 | 2024-01-09 | ライソゾーム病の遺伝子治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11807849B2 (enExample) |
| EP (1) | EP3692151A4 (enExample) |
| JP (4) | JP2020537542A (enExample) |
| KR (2) | KR20220010062A (enExample) |
| CN (2) | CN112501208A (enExample) |
| AU (3) | AU2018346102B2 (enExample) |
| BR (1) | BR112020006671A2 (enExample) |
| CA (1) | CA3078501A1 (enExample) |
| IL (2) | IL273768A (enExample) |
| MX (2) | MX2020004005A (enExample) |
| WO (1) | WO2019070891A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111542549A (zh) | 2017-10-03 | 2020-08-14 | 普利维尔治疗公司 | 用于溶酶体障碍的基因疗法 |
| MX2020004005A (es) | 2017-10-03 | 2020-10-05 | Prevail Therapeutics Inc | Terapias genicas para los trastornos lisosomales. |
| EP3692158A4 (en) | 2017-10-03 | 2021-08-04 | Prevail Therapeutics, Inc. | GENE THERAPIES FOR LYSOSOMAL DISEASES |
| CN113795575A (zh) | 2019-02-04 | 2021-12-14 | 自由行疗法有限公司 | 多核苷酸 |
| MX2021010134A (es) | 2019-02-22 | 2021-09-23 | Univ Pennsylvania | Virus adenoasociado recombinante para el tratamiento de la neurodegeneracion de inicio en adultos asociada a grn. |
| HRP20251506T1 (hr) | 2019-04-10 | 2026-01-02 | Prevail Therapeutics, Inc. | Genska terapija za lizosomske poremećaje |
| JP7664848B2 (ja) | 2019-04-10 | 2025-04-18 | プリベイル セラピューティクス，インコーポレーテッド | リソソーム障害のための遺伝子療法 |
| WO2021030522A1 (en) * | 2019-08-13 | 2021-02-18 | Alnylam Pharmaceuticals, Inc. | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
| AU2021325891A1 (en) | 2020-08-10 | 2023-04-06 | Prevail Therapeutics, Inc. | Gene therapies for neurodegenerative disorders |
| CN116157527A (zh) | 2020-08-10 | 2023-05-23 | 普利维尔治疗公司 | 用于溶酶体病症的基因疗法 |
| WO2022081985A1 (en) | 2020-10-15 | 2022-04-21 | Prevail Therapeutics, Inc. | Assay for measuring potency of gene therapy drug product |
| JP2023545830A (ja) | 2020-10-15 | 2023-10-31 | プリベイル セラピューティクス，インコーポレーテッド | 組換えアデノ随伴ウイルス組成物及びその生産方法 |
| TWI910261B (zh) * | 2020-11-06 | 2026-01-01 | 日商住友製藥股份有限公司 | Ｒｐｓ２５基因之表現及／或功能調節劑 |
| JP2024523445A (ja) * | 2021-06-21 | 2024-06-28 | ユニキュアー バイオファーマ ビー．ブイ． | α－シヌクレインをサイレンシングするための遺伝子構築物及びその使用 |
| US20240269161A1 (en) * | 2021-06-28 | 2024-08-15 | The Board Of Regents Of The University Of Texas System | Methods and compositions for tau reduction gene therapy |
| CN113846122B (zh) * | 2021-08-16 | 2023-08-25 | 中国医学科学院医学生物学研究所 | 一种过表达snca的腺相关病毒载体aav-snca、制备方法及其应用 |
| EP4493703A4 (en) * | 2022-03-18 | 2026-08-05 | Univ Florida | METHODS AND COMPOSITIONS FOR TREATING TMEM43-RELATED CARDIOMYOPATHY WITH A VIRAL VECTOR |
| KR20260085142A (ko) * | 2023-10-11 | 2026-06-08 | 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. | 미세소관 관련 단백질 tau(mapt)의 발현을 억제하기 위한 조성물 및 방법 |
| WO2025160429A1 (en) * | 2024-01-26 | 2025-07-31 | Genzyme Corporation | Artificial micrornas targeting snca |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5879680A (en) | 1987-12-23 | 1999-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Cloned DNA for synthesizing unique glucocerebrosidase |
| EP0933997A4 (en) * | 1996-09-06 | 2000-08-16 | Chiron Corp | METHODS AND COMPOSITIONS FOR LIVER-SPECIFIC ADMINISTRATION OF THERAPEUTIC MOLECULES USING RECOMBINANT AAV VECTORS |
| EP1112090A2 (en) | 1998-09-09 | 2001-07-04 | Myelos Corporation | Method of stimulating prosaposin receptor activity |
| WO2000023587A2 (en) | 1998-10-16 | 2000-04-27 | Introgene B.V. | Gene therapy of alzheimer's disease by delivery of an encoded apolipoprotein e |
| EP1135468B1 (en) | 1998-11-10 | 2010-01-06 | University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
| US6696272B1 (en) | 1999-06-02 | 2004-02-24 | Hsc Research & Development Limited Partnership | Products and methods for gaucher disease therapy |
| ATE387459T1 (de) | 2000-04-06 | 2008-03-15 | Kos Pharma Inc | Verbindungen und methoden zur senkung des cholesterinspiegels ohne induktion von hypertriglyceridämie |
| GB0009887D0 (en) * | 2000-04-20 | 2000-06-07 | Btg Int Ltd | Cytotoxic agents |
| JP2004514407A (ja) * | 2000-04-28 | 2004-05-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 異種キャプシド中にシュードタイピングされたａａｖ５キャプシドおよびａａｖ５ベクターを含む組換えａａｖベクター |
| ATE310096T1 (de) | 2000-09-18 | 2005-12-15 | Genzyme Corp | Expressionsvektoren mit hybriden ubiquitin- promotoren |
| US7232670B2 (en) | 2001-09-28 | 2007-06-19 | St. Jude Children's Research Hospital | Targeting proteins to cells expressing mannose receptors via expression in insect cells |
| CN103589692B (zh) * | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| US20030133924A1 (en) | 2001-12-21 | 2003-07-17 | Novazyme Pharmaceuticals, Inc. | Highly phosphorylated acid beta-glucocerebrosidase and methods of treating gaucher's disease |
| AU2003221733A1 (en) | 2002-04-17 | 2003-11-03 | University Of Florida Research Foundation, Inc. | Improved raav vectors |
| JP4979067B2 (ja) | 2003-05-01 | 2012-07-18 | ジェンザイム・コーポレーション | 神経代謝性疾患についての遺伝子治療 |
| WO2006036465A2 (en) | 2004-09-03 | 2006-04-06 | University Of Florida | Compositions and methods for treating cystic fibrosis |
| EP1799826B1 (en) | 2004-09-29 | 2009-08-12 | Children's Memorial Hospital | siRNA-MEDIATED GENE SILENCING OF ALPHA SYNUCLEIN |
| ES2485369T3 (es) | 2005-06-08 | 2014-08-13 | Amicus Therapeutics, Inc. | Tratamiento de trastornos del SNC asociados con mutaciones en genes que codifican enzimas lisosómicas |
| GB0605337D0 (en) * | 2006-03-17 | 2006-04-26 | Genomica Sau | Treatment of CNS conditions |
| EP2687223B2 (en) | 2006-05-30 | 2024-11-20 | Mayo Foundation For Medical Education And Research | Detecting and treating dementia |
| JP5123936B2 (ja) | 2006-05-30 | 2013-01-23 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 認知症の検出および治療 |
| HUE044182T2 (hu) | 2006-06-07 | 2019-10-28 | Genzyme Corp | Génterápia amiotrófiás laterális szklerózis és más gerincvelõ-rendellenességek kezelésére |
| WO2008124066A1 (en) | 2007-04-05 | 2008-10-16 | The J. David Gladstone Institutes | Agents that reduce neuronal overexcitation |
| EP2160403B1 (en) | 2007-05-11 | 2018-08-08 | Genzyme Corporation | Methods of producing a secreted protein |
| CN104383556B (zh) | 2007-05-16 | 2018-06-05 | 布里格姆妇女医院 | 突触核蛋白病的治疗 |
| US20090176729A1 (en) * | 2007-12-14 | 2009-07-09 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
| WO2009089635A1 (en) | 2008-01-16 | 2009-07-23 | Neurodyn, Inc. | Treating neurodegenerative diseases with progranulin (pgrn) |
| US9265843B2 (en) | 2008-03-27 | 2016-02-23 | The Ohio State University | Treatment of metabolic-related disorders using hypothalamic gene transfer of BDNF and compositions therefor |
| SI3988660T1 (sl) | 2009-05-02 | 2025-09-30 | Genzyme Corporation | Genska terapija za nevrodegenerativne motnje |
| WO2010129791A1 (en) * | 2009-05-06 | 2010-11-11 | University Of Medicine And Dentistry Of New Jersey | Rna targeting in alpha-synucleinopathies |
| DK2561073T3 (en) * | 2010-04-23 | 2016-12-12 | Univ Massachusetts | Aav vectors targeted to central nervous system and methods of use thereof |
| WO2012027558A2 (en) * | 2010-08-25 | 2012-03-01 | The Trustees Of Columbia University In The City Of New York | OPTIMIZED miRNA CONSTRUCTS |
| WO2012027713A2 (en) * | 2010-08-26 | 2012-03-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of snca |
| US10738326B2 (en) | 2010-10-27 | 2020-08-11 | Jichi Medical University | Adeno-associated virus vector for gene transfer to nervous system cells |
| CA2818253A1 (en) | 2010-11-16 | 2012-05-24 | Denis G. Kay | Method for increasing neprilysin expression and activity |
| GB201103062D0 (en) * | 2011-02-22 | 2011-04-06 | Isis Innovation | Method |
| CA2835707C (en) | 2011-05-09 | 2019-02-26 | Eip Pharma, Llc | Compositions and methods for treating alzheimer's disease |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US20150183850A1 (en) | 2012-05-18 | 2015-07-02 | University Of Iowa Research Foundation | Methods and compositions for treating amyloid deposits |
| US10648001B2 (en) | 2012-07-11 | 2020-05-12 | Sangamo Therapeutics, Inc. | Method of treating mucopolysaccharidosis type I or II |
| HK1214521A1 (zh) | 2012-11-05 | 2016-07-29 | Genzyme Corporation | 用於治療蛋白質病的組合物和方法 |
| AU2014251099B2 (en) * | 2013-04-08 | 2019-01-17 | The University Of Kansas | Chimeric adeno-associated virus/ bocavirus parvovirus vector |
| JP2016523835A (ja) | 2013-05-15 | 2016-08-12 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入 |
| US9347107B2 (en) | 2013-05-23 | 2016-05-24 | Norman Z Lai | Vector containing multiple nucleotide sequences for the expression of enzymes |
| US9951330B2 (en) | 2013-07-11 | 2018-04-24 | The Trustees Of Columbia University In The City Of New York | Micrornas that silence tau expression |
| US9574184B2 (en) | 2013-09-25 | 2017-02-21 | Children's Hospital Medical Center | Lysosomal protein targeting sequence and therapeutic applications of same |
| WO2015060722A1 (en) | 2013-10-24 | 2015-04-30 | Uniqure Ip B.V. | Aav-5 pseudotyped vector for gene therapy for neurological diseases |
| GB201403260D0 (en) * | 2014-02-25 | 2014-04-09 | Univ Manchester | Treatment of retinal degeneration using gene therapy |
| WO2016025523A1 (en) | 2014-08-11 | 2016-02-18 | Shire Human Genetic Therapies, Inc. | Lysosomal targeting and uses thereof |
| EP3215191B1 (en) * | 2014-11-05 | 2024-08-14 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
| EP3221456B1 (en) | 2014-11-21 | 2021-09-22 | University of Florida Research Foundation, Inc. | Genome-modified recombinant adeno-associated virus vectors |
| ES2820713T3 (es) * | 2015-03-25 | 2021-04-22 | Univ Degli Studi Di Trento | Terapia mediada por ARN interferente para enfermedades neurodegenerativas |
| US20170035860A1 (en) | 2015-04-02 | 2017-02-09 | Alexander C. Flynn | Compositions and methods for treatment of neurogenerative diseases |
| EP3285788B1 (en) | 2015-04-23 | 2024-12-18 | University of Massachusetts | Modulation of aav vector transgene expression |
| CA2985235A1 (en) | 2015-05-07 | 2016-11-10 | Shire Human Genetic Therapies, Inc. | Glucocerebrosidase gene therapy for parkinson's disease |
| EP3091087A1 (en) * | 2015-05-08 | 2016-11-09 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Method for in vitro diagnosis of synucleinopathies using alpha-synuclein gene transcripts |
| KR20220082100A (ko) | 2015-05-15 | 2022-06-16 | 리젠츠 오브 더 유니버시티 오브 미네소타 | 중추 신경계로의 아데노-연관 치료적 전달 |
| AU2016343979A1 (en) | 2015-10-29 | 2018-05-10 | Voyager Therapeutics, Inc. | Delivery of central nervous system targeting polynucleotides |
| SG10201912763QA (en) | 2015-11-05 | 2020-02-27 | Bamboo Therapeutics Inc | Modified friedreich ataxia genes and vectors for gene therapy |
| CA3011939A1 (en) | 2016-02-02 | 2017-08-10 | University Of Massachusetts | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system |
| HRP20231451T1 (hr) | 2016-02-05 | 2024-03-01 | Emory University | Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu |
| WO2017147509A1 (en) | 2016-02-25 | 2017-08-31 | Marco Colonna | Compositions comprising trem2 and methods of use thereof |
| CA3016314A1 (en) | 2016-03-02 | 2017-09-08 | Julianne REIDERS | Therapy for frontotemporal dementia |
| US11512327B2 (en) | 2017-08-03 | 2022-11-29 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of AAV |
| MX2020004005A (es) | 2017-10-03 | 2020-10-05 | Prevail Therapeutics Inc | Terapias genicas para los trastornos lisosomales. |
| CN111542549A (zh) | 2017-10-03 | 2020-08-14 | 普利维尔治疗公司 | 用于溶酶体障碍的基因疗法 |
| EP3692158A4 (en) | 2017-10-03 | 2021-08-04 | Prevail Therapeutics, Inc. | GENE THERAPIES FOR LYSOSOMAL DISEASES |
| US20200283800A1 (en) | 2017-10-23 | 2020-09-10 | Prevail Therapeutics, Inc. | Gene therapies for neurodegenerative diseases |
| AU2018354195A1 (en) | 2017-10-23 | 2020-06-04 | Prevail Therapeutics, Inc. | Gene therapies for neurodegenerative disease |
| CA3121211A1 (en) | 2018-11-28 | 2020-06-04 | Prevail Therapeutics, Inc. | Gene therapies for neurodegenerative disease |
| JP7664848B2 (ja) | 2019-04-10 | 2025-04-18 | プリベイル セラピューティクス，インコーポレーテッド | リソソーム障害のための遺伝子療法 |
| HRP20251506T1 (hr) | 2019-04-10 | 2026-01-02 | Prevail Therapeutics, Inc. | Genska terapija za lizosomske poremećaje |
| BR112021020157A2 (pt) | 2019-04-10 | 2021-12-14 | Prevail Therapeutics Inc | Terapias gênicas para transtornos lisossomais |
| US20220211871A1 (en) | 2019-04-10 | 2022-07-07 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
-
2018
- 2018-10-03 MX MX2020004005A patent/MX2020004005A/es unknown
- 2018-10-03 BR BR112020006671-0A patent/BR112020006671A2/pt not_active Application Discontinuation
- 2018-10-03 AU AU2018346102A patent/AU2018346102B2/en active Active
- 2018-10-03 US US16/753,018 patent/US11807849B2/en active Active
- 2018-10-03 CN CN202011187145.9A patent/CN112501208A/zh active Pending
- 2018-10-03 JP JP2020540681A patent/JP2020537542A/ja active Pending
- 2018-10-03 CN CN201880075728.7A patent/CN111465691A/zh active Pending
- 2018-10-03 KR KR1020227000760A patent/KR20220010062A/ko not_active Ceased
- 2018-10-03 EP EP18864256.5A patent/EP3692151A4/en active Pending
- 2018-10-03 KR KR1020207012192A patent/KR20200078513A/ko not_active Ceased
- 2018-10-03 WO PCT/US2018/054223 patent/WO2019070891A1/en not_active Ceased
- 2018-10-03 CA CA3078501A patent/CA3078501A1/en active Pending
-
2020
- 2020-04-02 US US16/838,993 patent/US12049626B2/en active Active
- 2020-04-02 IL IL273768A patent/IL273768A/en unknown
- 2020-07-13 MX MX2020011748A patent/MX2020011748A/es unknown
- 2020-10-29 AU AU2020260476A patent/AU2020260476B2/en active Active
- 2020-12-22 IL IL279669A patent/IL279669A/en unknown
-
2022
- 2022-01-21 JP JP2022007759A patent/JP2022060228A/ja active Pending
-
2023
- 2023-08-11 AU AU2023214366A patent/AU2023214366B2/en active Active
- 2023-11-13 JP JP2023192753A patent/JP2024014935A/ja active Pending
-
2024
- 2024-01-09 JP JP2024001041A patent/JP2024037189A/ja active Pending
- 2024-06-14 US US18/743,624 patent/US20250011783A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020537543A5 (enExample) | ||
| JP2020537544A5 (enExample) | ||
| JP2022060228A5 (enExample) | ||
| US11938197B2 (en) | Polynucleotides and vectors for the expression of transgenes | |
| US20220331451A1 (en) | Adeno-associated virus virions with variant capsid and methods of use thereof | |
| CN109715650B (zh) | 新颖腺相关病毒衣壳蛋白 | |
| FI3684423T3 (fi) | Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä | |
| JP2022508182A5 (enExample) | ||
| RU2021102893A (ru) | Модифицированные гены атаксии фридрейха и векторы для генной терапии | |
| US20230049066A1 (en) | Novel aav3b variants that target human hepatocytes in the liver of humanized mice | |
| CN101511373A (zh) | 用于基因治疗的修饰的因子viii和因子ix基因和载体 | |
| WO2022126189A1 (en) | Adeno-associated virus capsids and vectors | |
| KR20230019402A (ko) | 프로그래뉼린 연관 신경변성 질환 또는 장애의 치료를 위한 아데노-연관 바이러스 (aav) 시스템 | |
| TW202229315A (zh) | 改良的腺相關病毒(aav)載體及其用途 | |
| CN116096904A (zh) | 改进的aav-abcd1构建体和用于治疗或预防肾上腺脑白质营养不良(ald)和/或肾上腺脊髓神经病(amn)的用途 | |
| JP2021520811A5 (enExample) | ||
| JP2023539247A (ja) | Ｇｌｐ－１受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用 | |
| CN120548368A (zh) | 用于正确包装重复元件的腺相关病毒载体 | |
| CN119487183A (zh) | 用于生产重组细小病毒的组合物和方法 | |
| CN118414348A (zh) | 经修饰的aav衣壳和载体 | |
| US20240425879A1 (en) | Compositions and methods for adeno-associated (aav) virus dnase expression | |
| CN119306807A (zh) | 一种变体AAV衣壳蛋白、重组腺相关病毒rAAV | |
| EP4582546A1 (en) | Adeno-associated virus structural plasmid capable of improving adeno-associated virus titer | |
| CN117836312A (zh) | 分离的修饰的aav9衣壳蛋白vp1 | |
| KR102874560B1 (ko) | 아데노연관바이러스 변이체 |